Tisagenlecleucel Therapy For Non-Hodgkin Lymphoma Approved By FDA – ReliaWire
ReliaWire |
Tisagenlecleucel Therapy For Non-Hodgkin Lymphoma Approved By FDA
ReliaWire The CAR T-cell therapy tisagenlecleucel, marketed as Kymriah, was recently approved by the FDA for adults with certain types of non-Hodgkin lymphoma. This is the second CAR T-cell therapy approved for lymphoma and the second FDA approval for this … |
